Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
about
Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient PharmaceuticalsClinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis.Fixed-dose combination and single active ingredient drugs: a comparative cost analysis.Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis
P2860
Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical and economic outcomes ...... n system blocker combinations.
@en
type
label
Clinical and economic outcomes ...... n system blocker combinations.
@en
prefLabel
Clinical and economic outcomes ...... n system blocker combinations.
@en
P2093
P2860
P356
P1476
Clinical and economic outcomes ...... n system blocker combinations.
@en
P2093
Carlos M Ferrario
Jason P Swindle
Paul Buzinec
Sumeet Panjabi
P2860
P356
10.1177/1753944712470979
P577
2013-01-17T00:00:00Z